The Cost-Effectiveness of Multi-Gene Panel Sequencing in Advanced Non-Small Cell Lung Cancer: A Peer-Reviewed Study

PMC commissioned the first economic modeling study to estimate the cost-effectiveness of “multi-gene panel sequencing” (MGPS) as compared to standard-of-care, single-gene tests for patients with advanced non-small cell lung cancer (aNSCLC), showing that the MGPS tests are moderately cost-effective but could deliver more value if patients with test results identifying actionable genetic mutations consistently received genetically guided treatments. The results of the study, which were published in JCO Clinical Cancer Informatics, underline the need to align clinical practices with an era of personalized medicine.